A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors.
about
Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cellsSapacitabine for cancerAntineovascular therapy with angiogenic vessel-targeted polyethyleneglycol-shielded liposomal DPP-CNDAC.Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types.Development of an oral form of azacytidine: 2'3'5'triacetyl-5-azacytidine.Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome.Outpatient chemotherapy plus radiotherapy in sarcomas: improving cancer control with radiosensitizing agents.Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaksFailure of hypomethylating agent-based therapy in myelodysplastic syndromes.Profile of sapacitabine: potential for the treatment of newly diagnosed acute myeloid leukemia in elderly patients.
P2860
Q24653228-6EB0F4A0-0718-49A7-AA4F-AE992124DC9CQ27024675-3134F9A8-6666-47EB-A3BB-C3D864860C28Q33320876-00E3DCA0-13BC-4AF8-BCD6-2B4C2B9DFAADQ34344158-00707DEF-940C-4AA4-9B64-7782C20F569BQ35687461-8ED6DED1-AA10-4963-A8C8-1F0DD3E7FF35Q35924564-BA54AED2-1E9F-401D-AA1B-872999D4888DQ37038352-3CB6D1A3-C25C-4142-BA9F-8ADA0871ED2DQ37183758-EBFE8516-3793-48FA-A189-06698DC22B92Q37937816-5A68B72D-C9BC-4B5C-8429-4213BAF1AAB3Q38213704-E255326C-0498-4320-AEF7-ECC6EE73F221
P2860
A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
A phase I clinical and pharmac ...... vanced malignant solid tumors.
@ast
A phase I clinical and pharmac ...... vanced malignant solid tumors.
@en
type
label
A phase I clinical and pharmac ...... vanced malignant solid tumors.
@ast
A phase I clinical and pharmac ...... vanced malignant solid tumors.
@en
prefLabel
A phase I clinical and pharmac ...... vanced malignant solid tumors.
@ast
A phase I clinical and pharmac ...... vanced malignant solid tumors.
@en
P2093
P1476
A phase I clinical and pharmac ...... vanced malignant solid tumors.
@en
P2093
Charles Erlichman
Joel M Reid
John K Camoriano
Joseph Rubin
Judith S Kaur
Patrick A Burch
Theodore A Braich
Thierry Delaunoit
Tomowo Kobayash
P2888
P304
P356
10.1007/S10637-006-5392-0
P577
2006-07-01T00:00:00Z
P6179
1019644669